Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX)

Historical Holders from Q1 2022 to Q3 2025

Symbol
AMLX on Nasdaq
CUSIP
03237H101
Type / Class
Equity / COMMON STOCK
Shares outstanding
106M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
81.7M
Holdings value
$524M
% of all portfolios
0.005%
Grand Portfolio weight change
+0%
Number of holders
130
Number of buys
67
Number of sells
-74
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 10.7% $155M 11.4M FMR LLC Sep 30, 2025
Adage Capital Management, L.P. 9.87% +57.3% $56.4M $19.9M 8.8M +54.5% Adage Capital Management, L.P. Jun 30, 2025
PERCEPTIVE ADVISORS LLC 8.8% +11.3% $27.5M $3.84M 7.87M +16.2% Perceptive Advisors LLC Mar 31, 2025
BlackRock, Inc. 5.5% $25.3M 4.92M BlackRock, Inc. Jun 30, 2025
Point72 Asset Management, L.P. 5.3% +410% $24.3M $18.9M 4.72M +350% Point72 Asset Management, L.P. Jun 24, 2025
VANGUARD GROUP INC 5.04% $23.2M 4.5M The Vanguard Group Jun 30, 2025
Panacea Innovation Ltd 2.6% $7.68M 2.2M Panacea Venture Healthcare Fund II, L.P. Dec 31, 2024

Institutional Holders of Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 13.7K $187K -$85.6K $13.59 5
2025 Q2 81.7M $524M +$57.3M $6.41 130
2025 Q1 73.9M $262M +$85.1M $3.54 134
2024 Q4 49.8M $188M +$19.5M $3.78 120
2024 Q3 43.4M $141M +$5.13M $3.24 109
2024 Q2 43.6M $82.9M -$16.9M $1.90 119
2024 Q1 49.5M $141M -$233M $2.84 145
2023 Q4 33.5K $493K -$16.7M $14.72 2
2023 Q3 58.9M $1.08B +$85.4M $18.31 168
2023 Q2 54.5M $1.17B +$53.6M $21.57 152
2023 Q1 51.4M $1.51B +$73.7M $29.34 145
2022 Q4 48.5M $1.79B +$430M $36.95 130
2022 Q3 36.6M $1.03B +$308M $28.15 88
2022 Q2 26.6M $513M +$61.9M $19.26 73
2022 Q1 23.3M $299M +$299M $12.85 70